Amgen (AMGN) VP Finance & CAO Matthew Busch Receives RSU Award

What Happened

• Matthew C. Busch, Vice President, Finance & Chief Accounting Officer of Amgen, was granted 730 restricted stock units (RSUs) on 2026-08-07. The award is recorded at $0.00 in the filing (standard for RSU grants; no cash purchase). The RSUs will convert to shares on a one-to-one basis as they vest.

Key Details

• Transaction date: 2026-08-07; Filing date (Form 4): 2026-08-12 (appears to be filed after the typical two-business-day deadline).
• Grant amount: 730 RSUs; grant price shown: $0.00.
• Includes 45 Dividend Equivalents (DEs) credited to the unvested RSUs and paid in shares per the vesting schedule (plus cash for any fractional share).
• Vesting: Four equal annual installments of 25% each, commencing 8/7/2027; vested RSUs paid in shares one-for-one.
• Shares owned after the transaction: not stated in the provided filing excerpt.

Context

• RSU grants are a form of compensation, not an open-market purchase or sale. They typically vest over time and are common for executives; they do not by themselves imply a buy/sell signal.
• Dividend Equivalents increase the eventual share payout tied to the RSUs and follow the same vesting schedule.
• The filing date suggests the Form 4 was submitted several days after the grant date, which may be later than the usual two-business-day reporting requirement.